See the DrugPatentWatch profile for wegovy

Wegovy vs Ozempic: A Comprehensive Comparison of Semaglutide and Semaglutide

What is Wegovy?

Wegovy is a medication used to treat obesity, specifically for adults with a body mass index (BMI) of 30 or higher, or 27 or higher with at least one weight-related condition. It is a once-weekly injection of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Wegovy is manufactured by Novo Nordisk and was approved by the FDA in June 2021.

What is Ozempic?

Ozempic is a medication used to treat type 2 diabetes, as well as cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease. It is also a once-weekly injection of semaglutide, a GLP-1 receptor agonist. Ozempic is manufactured by Novo Nordisk and was approved by the FDA in 2017.

Key Differences

While both Wegovy and Ozempic contain the same active ingredient, semaglutide, they have different indications and dosing regimens.

Indications

* Wegovy: Obesity
* Ozempic: Type 2 diabetes and cardiovascular risk

Dosing Regimen

* Wegovy: 2.4 mg once weekly
* Ozempic: 0.5 mg, 1 mg, or 2 mg once weekly, depending on the indication and patient population

Mechanism of Action

Both Wegovy and Ozempic work by mimicking the action of GLP-1, a natural hormone that helps regulate glucose levels and appetite. They stimulate the release of insulin, reduce glucagon secretion, and slow gastric emptying, leading to improved glucose control and weight loss.

Clinical Trials

Wegovy was studied in the STEP-WT trial, which included over 2,600 adults with obesity. The trial showed that Wegovy resulted in significant weight loss, with a mean weight loss of 15.3% at 68 weeks. Ozempic was studied in the SUSTAIN-6 trial, which included over 3,000 adults with type 2 diabetes. The trial showed that Ozempic reduced the risk of major adverse cardiovascular events by 26%.

Side Effects

Common side effects of Wegovy and Ozempic include:

* Nausea
* Injection site reactions
* Diarrhea
* Abdominal pain
* Headache

Cost

Wegovy is a more expensive medication than Ozempic, with a list price of around $1,000 per month. Ozempic has a list price of around $500 per month.

Conclusion

Wegovy and Ozempic are both semaglutide-based medications that have shown promising results in clinical trials. While they share some similarities, they have different indications and dosing regimens. Wegovy is specifically approved for obesity, while Ozempic is approved for type 2 diabetes and cardiovascular risk. Patients should consult with their healthcare provider to determine which medication is right for them.

FAQs

Q: What is the difference between Wegovy and Ozempic?

A: Wegovy is specifically approved for obesity, while Ozempic is approved for type 2 diabetes and cardiovascular risk.

Q: How do Wegovy and Ozempic work?

A: Both medications work by mimicking the action of GLP-1, a natural hormone that helps regulate glucose levels and appetite.

Q: What are the common side effects of Wegovy and Ozempic?

A: Common side effects include nausea, injection site reactions, diarrhea, abdominal pain, and headache.

Q: How much does Wegovy cost?

A: Wegovy has a list price of around $1,000 per month.

Q: How much does Ozempic cost?

A: Ozempic has a list price of around $500 per month.

Q: Can I take Wegovy if I have type 2 diabetes?

A: No, Wegovy is specifically approved for obesity and is not indicated for type 2 diabetes. Patients with type 2 diabetes should consult with their healthcare provider about Ozempic or other appropriate treatments.

Sources:

1. Novo Nordisk. (2021). Wegovy Prescribing Information.
2. Novo Nordisk. (2021). Ozempic Prescribing Information.
3. DrugPatentWatch.com. (2022). Semaglutide Patent Expiration.
4. FDA. (2021). FDA Approves Wegovy for Chronic Weight Management.
5. FDA. (2017). FDA Approves Ozempic to Improve Glycemic Control in Adults with Type 2 Diabetes.